首页> 外文期刊>Journal of postgraduate medicine >Detection of fetal mutations causing hemoglobinopathies by non-invasive prenatal diagnosis from maternal plasma
【24h】

Detection of fetal mutations causing hemoglobinopathies by non-invasive prenatal diagnosis from maternal plasma

机译:通过产妇血浆的非侵入性产前诊断检测导致血红蛋白病的胎儿突变

获取原文
获取原文并翻译 | 示例
           

摘要

Background: Prenatal diagnosis of hemoglobinopathies enables couples at risk to have a healthy child. Currently used fetal sampling procedures are invasive with some risk of miscarriage. A non-invasive approach to obtain fetal deoxyribonucleic acid (DNA) for diagnosis would eliminate this risk. Aim: To develop and evaluate a non-invasive prenatal diagnostic approach for hemoglobinopathies using cell-free fetal DNA circulating in the maternal plasma. Settings and Design: Couples referred to us for prenatal diagnosis of hemoglobinopathies where the maternal and paternal mutations were different were included in the study. Materials and Methods: Maternal peripheral blood was collected at different periods of gestation before the invasive fetal sampling procedure was done. The blood was centrifuged to isolate the plasma and prepare DNA. A size separation approach was used to isolate fetal DNA. Nested polymerase chain reaction (PCR)-based protocols were developed for detection of the presence or absence of the paternal mutation. Results and Conclusions: There were 30 couples where the parental mutations were different. Of these, in 14 cases the paternal mutation was absent and in 16 cases it was present in the fetus. Using cell-free fetal DNA from maternal plasma, the absence of the paternal mutation was accurately determined in 12 of the 14 cases and the presence of the paternal mutation was correctly identified in 12 of the 16 cases. Thus, this non-invasive approach gave comparable results to those obtained by the conventional invasive fetal sampling methods in 24 cases giving an accuracy of 80.0%. Although the nested PCR approach enabled amplification of small quantities of cell-free DNA from maternal plasma at different periods of gestation after size separation to eliminate the more abundant maternal DNA, an accurate diagnosis of the presence or absence of the paternal mutation in the fetus was not possible in all cases to make it clinically applicable.
机译:背景:血红蛋白病的产前诊断可以使处于危险中的夫妇生育一个健康的孩子。当前使用的胎儿采样程序是侵入性的,具有一定的流产风险。以非侵入性方式获得胎儿脱氧核糖核酸(DNA)进行诊断将消除这种风险。目的:使用母体血浆中循环的无细胞胎儿DNA,开发和评估血红蛋白病的非侵入性产前诊断方法。设置与设计:夫妻转介给我们进行产前血红蛋白病的诊断,其中母体和父体突变不同。材料和方法:在进行有创胎儿采样程序之前,在妊娠的不同时期收集孕妇外周血。将血液离心以分离血浆并制备DNA。使用大小分离方法来分离胎儿DNA。开发了基于巢式聚合酶链反应(PCR)的方案,用于检测是否存在父系突变。结果与结论:共有30对夫妻的亲本突变不同。其中,在14例中没有父系突变,在16例中存在于胎儿中。使用来自母体血浆的无细胞胎儿DNA,在14例中的12例中准确地确定了没有父本突变,在16例中的12例中正确地鉴定了父本突变。因此,在24例病例中,这种非侵入性方法的结果与常规侵入性胎儿采样方法所获得的结果相当,准确性为80.0%。尽管巢式PCR方法能够在大小分离后的不同妊娠期从母体血浆中扩增少量无细胞DNA,以消除更丰富的母体DNA,但仍可以准确诊断胎儿中是否存在母体突变不可能在所有情况下都使其在临床上适用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号